ArticleThe oncologist2026

Clinical and molecular response to vorasidenib in post-transplant patient with IDH2-mutant intrahepatic cholangiocarcinoma.

Vivian V Altiery De Jesus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.